The main limitation of PD-L1 assessment by IHC analysis is that it only reflects one single aspect of intratumor immune suppression, i.e., the binding of PD-L1 in cancer cells and/or macrophages to PD1 on tumor-infiltrating T lymphocytes, which results in immunosuppressive effects. This evidence concerns the gene CD274 and cancer.